



Admedus Ltd
ABN 35 088 221 078

REGISTERED OFFICE:
26 Harris Road
MalagaWestern Australia6090
PO Box 6879
East Perth Western Australia 6892

T +61 (0)8 9266 0100
F +61 (0)8 9266 0199

Info.au@admedus.com

www.admedus.com

COMPANY ANNOUNCEMENT

ADMEDUS RENOUNCEABLE RIGHTS ISSUE NOW OPEN

Brisbane, Australia, 18 August 2016

Admedus Limited (**Admedus** or **Company**) (ASX: AHZ) announces today that its fully underwritten 1 for 9 Rights Issue to eligible shareholders to raise approximately \$8.3 million opens today and will close at 3.00pm (WST) on 29 August 2016. In conjunction with the Rights Issue, Admedus recently completed a Placement of \$10 million which ensures that the Company is in a strong financial position.

Admedus is focused on continued growth of sales across the company and is expecting at least a 50% growth in revenue in the 2017 financial year, along with expanding its near market product portfolio. Admedus is also well advanced in the restructuring and cost reduction initiatives announced to the market on 20 July 2016.

"The Board and I thank new and existing shareholders for their support as we direct the Company towards sustainability and continued growth. Admedus has great technologies and best in class products which we are leveraging to global commercial success as we continue to build a credible Australian global healthcare company," said Mr Wayne Paterson, Chair and Interim CEO.

The prospectus and personalised entitlement and acceptance forms for the Rights Issue will be dispatched to eligible shareholders today and should be received in the next 3 days. Those eligible shareholders who have not received a prospectus and entitlement and acceptance form in that time frame should contact the Company via the details below. Eligible shareholders are also able to apply for additional shares in excess of their entitlement through the Rights Issue.

The closing price of the Company's shares on 9 August 2016 was 32.5c which is below the issue price for Rights Issue shares of 33c. Whilst this triggers a termination right, as disclosed in the Prospectus dated 2 August 2016, we note that the closing price of the Company shares on 17 August was \$0.335 and the Rights Issue continues to be fully underwritten by Patersons Securities Limited.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

Website: www.admedus.com

Blog: www.admedus.com/au/category/news/

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 (0)8 9266 0100

Media:

Shevaun Cooper | PR Manager | Admedus Limited

Tel: +61 (0) 417 985 599 | Email: scooper@admedus.com

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

US Investor

Rx Communications Group, LLC

Melody A. Carey

+1 917 322 2571

mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The Company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the Company can be found on www.admedus.com.